It has been hypothesized that the receptor binding and functional profile of brexpiprazole at these receptors may make brexpiprazole a better choice for adjunctive treatment of MDD than other products commonly used when there is insufficient response to antidepressants alone15 because of the known antidepressant and anxiolytic effects of 5‐HT1A receptor partial agonists and 5‐HT2A receptor antagonists.16 The gene discussed is HTR1A; the disease is major depressive disorder.